ACM
SLNO

Atika Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Atika Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-650
Closed -$4.64M – 76
2025
Q1 		$4.64M Buy
+650
New +$31.6K 0.65% 49

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Atika Capital Management's SLNO Position: Q3 2025 in Review

Atika Capital Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 120,500 shares — an estimated $10.1M sold.

Atika Capital Management first reported a position in SLNO in Q4 2024 and held it in 3 quarters. The position peaked at $10.1M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Atika Capital Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Atika Capital Management sold 120,500 Soleno Therapeutics shares in Q3 2025, an estimated $10.1M.
  • Atika Capital Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 3 quarters.
  • Atika Capital Management's Soleno Therapeutics position peaked at $10.1M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Atika Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.